Senseonics Holdings announced a strategic shift to bring the commercialization of its Eversense 365 continuous glucose monitoring system in-house, signing a memorandum of understanding with current distributor Ascensia Diabetes Care to transition all global sales and marketing operations beginning January 1, 2026.
The move represents a significant milestone for the medical technology company's flagship product, Eversense 365, which stands as the world's first and only year-long implantable continuous glucose monitor. Since 2020, Ascensia has held exclusive worldwide distribution rights for Eversense products, but the companies have determined that the CGM business requires more focused commercial investment and strategic alignment.
Commercial Leadership Transition
Brian Hansen, who has served as President of CGM at Ascensia since February 2024 and previously held the position of Chief Commercial Officer at Tandem Diabetes Care, will join Senseonics as Chief Commercial Officer on January 1, 2026. This leadership continuity is designed to ensure a smooth transition of the commercial team and operations.
"I'm thrilled to bring Eversense 365 commercialization back in-house and directly control investment in growing the brand to better serve the needs of patients and providers," stated Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. "With Brian to remain at the helm of Senseonics' commercialization efforts, we are confident that this move will yield benefits for our customers and our shareholders."
Strategic Rationale and Market Position
The transition reflects the evolving needs of the Eversense business as awareness continues to grow following the Eversense 365 approval. According to company leadership, the go-to-market approach has increasingly diverged from Ascensia's core blood glucose monitoring business, creating an opportunity for more targeted commercial investment.
Koichiro Sato, Chief Operating Officer and Chief Strategy Officer of PHC Group and CEO of Ascensia Diabetes Care, expressed support for the transition: "We are very proud to have worked with Senseonics on commercializing Eversense and are committed to supporting Senseonics in establishing their own commercial operations and smoothly transitioning to them under the planned agreements."
Financial Projections and Funding
The commercial transition is expected to deliver immediate financial benefits through improved revenue capture and margin expansion. By eliminating Ascensia revenue sharing arrangements, Senseonics projects gross margin expansion to 50% in 2026, with plans to achieve more than 70% gross margins at scale.
To support the commercial organization buildout, Senseonics has secured an expanded $100 million non-dilutive debt facility with Hercules Capital. The investments in commercial infrastructure will be funded through a combination of improved margins and this expanded credit facility.
2025 Financial Outlook
Senseonics maintains its full-year 2025 global net revenue guidance of approximately $34-38 million as the company continues rolling out Eversense 365 to U.S. patients. The financial outlook assumes approximately doubling of the global patient base during 2025, with revenue distribution weighted toward the second half of the year.
The company expects approximately one-third of revenue to be generated in the first half of 2025 and two-thirds in the second half, with fourth quarter revenue particularly strong due to the one-time shift to once-a-year Eversense 365 reorder dynamics following its Q4 2024 launch.
Gross margins are projected to increase throughout 2025, reaching between 32.5% and 37.5% for the full year. Cash used in operations for 2025 is expected to be approximately $60 million.
Product Specifications and Market Access
The Eversense CGM systems include Eversense 365, which provides continuous glucose monitoring for up to 365 days, and Eversense E3, which monitors for up to 180 days. Both systems are indicated for persons with diabetes age 18 and older and can replace fingerstick blood glucose measurements for diabetes treatment decisions.
The systems feature a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor, automatically sending glucose data every 5 minutes to a mobile app on the user's smartphone. Sensor insertion and removal procedures are performed by healthcare providers.
Implementation Timeline
Under the memorandum of understanding, Senseonics will assume responsibility for all global sales, marketing and commercialization in the U.S. beginning January 1, 2026. For markets outside the U.S., the company will utilize Transition Service Agreements through Ascensia until fully established in those regions.
The companies are currently working together to develop definitive documentation for the planned transaction, with management scheduled to host an investor call on September 4, 2025, to discuss the commercial transition details.
